In this context, Infante et al. (2016) compared the transcriptome of carriers of the LRRK2 G2019S mutation (symptomatic and asymptomatic) as well as PD patients without the G2019S mutation and controls. This evidence concerns the gene LRRK2 and Parkinson disease.